🔎 Trials Near Me

Acasă › Limfom Burkitt › District of Columbia

Studii clinice pentru Limfom Burkitt în District of Columbia

5 studii pentru Limfom Burkitt caută participanți în District of Columbia.

Orașe în District of Columbia

Text oficial al studiului (în engleză)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • MedStar Georgetown University Hospital, Washington D.C.
  • Children's National Medical Center, Washington D.C.
În curs de recrutareFaza 2
366 Days – 46 Years · Toate sexele · Actualizat 2 oct. 2026 · NCT06124157

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • MedStar Georgetown University Hospital, Washington D.C.
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 29 sept. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Children's National Medical Center, Washington D.C.
În curs de recrutareFaza 2
365 Days · Toate sexele · Actualizat 25 sept. 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's National Medical Center, Washington D.C.
În curs de recrutareFaza 2
Vârste de la 1 la 30 · Toate sexele · Actualizat 1 sept. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Children's National Medical Center, Washington D.C.
În curs de recrutareFaza 3
365 Days – 25 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03959085

Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.